As shown in Desk 3Desk 3Clinical Outcomes at 12 months., everolimus-eluting stents, as compared with paclitaxel-eluting stents, had been superior with regards to the main end stage of the 1-year rate of target-lesion failure and with respect to the major secondary end point of ischemia-driven target-lesion revascularization at 1 year . Everolimus-eluting stents, as compared with paclitaxel-eluting stents, were noninferior with respect to the main secondary end point of cardiac loss of life or target-vessel myocardial infarction at 1 year, although this difference did not reach superiority .Nevertheless, whether these clumps are enough to trigger neurodegeneration, and how these clumps spread throughout the brain, remained unclear. Related StoriesPresence of connexin proteins suppresses principal tumor growthProtein sensor for proprioception foundUnique, tiny protein cage developed to deliver chemotherapy chemicals to tumor cellsTo answer these queries directly, a united team led by Virginia M.Y. Lee at the University of Pennsylvania School of Medication studied mice expressing a mutated form of alpha-synuclein found in sufferers with Parkinson’s disease. These mice present symptoms of disease around one year of age but not previously. Lee and colleagues found that injecting preformed clumps of individual alpha-synuclein into the brains of young mice accelerated disease starting point and intensity.